Since the discovery of EML4-ALK oncogenic fusion, several small molecule ALK inhibitors have been developed and approved for the treatment of ALK-positive NSCLC patients including, crizotinib (1st generation), ceritinib, alectinib, and brigatinib (2nd generation), and lorlatinib (LOR, 3rd generation) [8]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.